Phase 2 Evidence and Impact Analysis
Article 1 — Puccini et al. — PROSIT study (PMID: 42966319)
Immune Exclusion signature in stage II colon cancer | Prospective clinical-trial correlative transcriptomic study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | IE signature predicting DFS independent of MSI/sidedness is a meaningful refinement in a molecularly crowded space; not entirely new territory but adds prospective trial-linked evidence |
| Clinical Relevance | 7 | Stage II CRC adjuvant decisions are a persistent clinical dilemma; an immune signature tied to DFS could reshape chemotherapy selection |
| Population Reach | 6 | Stage II CRC is common (~130,000 new US cases/year); "high-risk" subset narrows reach but is still substantial |
| Implementation Speed | 5 | Transcriptomic profiling requires lab infrastructure, regulatory clearance, and prospective validation before clinical deployment |
| Evidence Strength | 7 | Prospective, trial-embedded design (TOSCA phase III) is a strong methodological foundation; abstract-only access limits full confidence |
Key quantitative result: IE signature associated with significantly shorter DFS; adjusted for MSI status and tumor sidedness — effect size not extractable from abstract. Validation status: Embedded in a phase III trial cohort; not independently externally replicated yet. Main limitation: Abstract-only; sample size unreported; survival follow-up duration unclear; single-country/trial cohort limits generalizability. Equity implications: Transcriptomic profiling costs and infrastructure inequities could limit access for patients in lower-resource settings; rural patients and underserved systems may face delays. Evidence Maturity: Validated ✓ (confirmed — prospective trial-embedded design is appropriate for this label)
Article 2 — Chen et al. — FFL in diabetic kidney disease (PMID: 42966155)
Fucoidan/fucoxanthin/l-carnitine in DKD | Proof-of-concept RCT + preclinical
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Marine-derived compound combination is novel in DKD; l-carnitine and fucoidans individually studied, but this triple combination is less well characterized |
| Clinical Relevance | 6 | DKD is a major unmet need; LDL reduction and eGFR preservation are meaningful endpoints, but proof-of-concept size and 12-week horizon limit impact |
| Population Reach | 7 | Diabetic kidney disease affects ~40% of people with diabetes globally — enormous population |
| Implementation Speed | 4 | Dietary supplements could deploy rapidly in principle, but regulatory pathway for therapeutic claims and larger RCTs needed first |
| Evidence Strength | 5 | Proof-of-concept RCT is encouraging but underpowered for clinical conclusions; mixed species design adds uncertainty |
Key quantitative result: LDL GMR 0.85 (95% CI: 0.76–0.95; p<0.01); up to 24.28% LDL reduction in dyslipidemics. Validation status: No external replication; single proof-of-concept trial. Main limitation: Small, short-duration, proof-of-concept only; sample size not reported in abstract; mixed-species design; 12 weeks insufficient to assess hard renal outcomes. Equity implications: If effective, supplement-based therapies could be lower-cost; however, unclear pricing, formulation availability, and absence of data in non-Asian populations limits generalizability. Evidence Maturity: Revised → Exploratory (label of "Validated" overstates a proof-of-concept RCT)
Article 3 — Kajiura et al. — Japan C-CAT CGP reference (PMID: 42965781)
Nationwide CGP alteration frequencies in Japan | Retrospective cohort
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Descriptive reference dataset; valuable infrastructure but not a discovery study |
| Clinical Relevance | 5 | Provides population-level reference frequencies useful for interpreting CGP results; indirect clinical utility |
| Population Reach | 6 | Applicable across cancer types tested in Japan's CGP pathway; relevant internationally as a comparator dataset |
| Implementation Speed | 6 | Reference data is immediately usable by clinicians interpreting CGP reports |
| Evidence Strength | 6 | Nationwide registry gives large-scale coverage; retrospective and abstract-only limits full appraisal |
Key quantitative result: Descriptive alteration frequencies; no comparative effect size reported. Validation status: Single-country descriptive; no external validation applicable. Main limitation: Japan-specific; ethnic/genomic differences limit direct applicability to non-Japanese populations; non-ICI-specific scope narrows clinical utility focus. Equity implications: Strengthens genomic medicine infrastructure in Japan; less relevant to populations in settings without CGP access; could serve as a model for other national programs. Evidence Maturity: Validated ✓ (appropriate for descriptive reference data)
Article 4 — Massalha et al. — Local ablation in NSCLC oligoprogression (PMID: 42965526)
LAT during immunotherapy for oligoprogressive mNSCLC | Systematic review + meta-analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Strategy of continuing IO + adding local ablation is not conceptually new, but this meta-analysis consolidates evidence and refines the signal |
| Clinical Relevance | 7 | Oligoprogression during IO is a daily clinical challenge; even modest PFS/OS gains are practice-relevant in mNSCLC |
| Population Reach | 7 | NSCLC is the most common cause of cancer death globally; IO-treated patients with oligoprogression represent a large and growing subgroup |
| Implementation Speed | 6 | Local ablative treatments (SBRT, RFA) are already in clinical use; adoption could be rapid if guideline-supported |
| Evidence Strength | 5 | Meta-analysis based predominantly on observational, low-certainty evidence; lacks RCT-level support |
Key quantitative result: Improved PFS and OS associated with LAT; exact HR/CI not extractable from abstract. Validation status: Synthesizes existing literature; no new primary data; evidence base is observational. Main limitation: Low-certainty, predominantly observational evidence base; publication bias risk; heterogeneity in ablative modalities, IO agents, and patient selection likely high. Equity implications: Ablative procedures require specialized equipment and expertise; access inequities in low-resource settings and rural areas could limit benefit. Evidence Maturity: Revised → Exploratory (low-certainty observational synthesis does not warrant "Validated")
Article 5 — John et al. — Gut microbiome in CHD newborns (PMID: 42966652)
SES and feeding on gut microbiome in CHD neonates | Prospective matched cohort (secondary analysis)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Intersection of CHD, SES, gut microbiome, and feeding is relatively novel and clinically meaningful |
| Clinical Relevance | 5 | Identifies modifiable factors (feeding method) but does not yet link microbiome changes to outcomes |
| Population Reach | 4 | CHD affects ~1% of births; relevant but rare disease context |
| Implementation Speed | 5 | Breastfeeding promotion and feeding tube minimization are feasible; SES interventions are complex |
| Evidence Strength | 5 | Prospective matched design is solid for this field; secondary analysis limits causal inference |
Key quantitative result: Feeding tubes, formula, aortic cross-clamp time, and SES associated with reduced microbiome diversity; effect sizes not reported in abstract. Main limitation: Secondary analysis; causality between microbiome disruption and outcomes not established; small population. Equity implications: SES explicitly modeled as a predictor — directly highlights health equity dimensions; findings particularly relevant to lower-income families. Evidence Maturity: Exploratory ✓
Article 6 — Haber et al. — Low-dose vs standard-dose alteplase in PE (PMID: 42966650)
Alteplase dosing in high-risk PE | Retrospective cohort
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Low-dose thrombolysis is an active research question; retrospective data adds to but doesn't resolve the debate |
| Clinical Relevance | 7 | High-risk PE carries ~30% mortality; if low-dose is non-inferior with less bleeding, practice implications are immediate |
| Population Reach | 6 | High-risk PE is an emergency medicine and critical care staple; affects tens of thousands annually in the US |
| Implementation Speed | 6 | Alteplase is already available; dose adjustment is operationally simple if evidence supports it |
| Evidence Strength | 4 | Retrospective cohort; confounding by indication likely; high mortality in both groups (45–48%) suggests very sick patients; small sample inferred |
Key quantitative result: In-hospital mortality 48% (low-dose) vs. 45% (standard-dose), p=0.81 — no significant difference detected, but study likely underpowered. Main limitation: Retrospective design; no bleeding outcomes reported in abstract; likely underpowered; selection bias for which patients received low vs. standard dose. Equity implications: Simpler/safer dosing protocols could improve care in lower-resourced settings; no equity analysis reported. Evidence Maturity: Exploratory ✓
Article 7 — Greathouse et al. — Dysphagia and high-flow nasal cannula (PMID: 42966646)
HFNC and dysphagia risk in ICU | Retrospective chart audit
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Dysphagia in HFNC patients has been raised before; chart audit adds quantification but limited new insight |
| Clinical Relevance | 6 | Dysphagia is underrecognized in ICU; association with prolonged stay and intubation is clinically actionable |
| Population Reach | 5 | HFNC use is widespread in ICUs globally; dysphagia screening is widely applicable |
| Implementation Speed | 7 | Swallowing screening is low-cost and implementable quickly |
| Evidence Strength | 3 | Retrospective chart audit is among the weakest designs; no causal inference possible |
Main limitation: Retrospective audit; causality unclear (dysphagia may predate HFNC or result from underlying illness rather than HFNC itself). Equity implications: ICU-acquired complications disproportionately affect vulnerable patients; dysphagia screening protocols need equity-conscious implementation. Evidence Maturity: Exploratory ✓
Article 8 — Adams et al. — Hospital-acquired anemia in ICU (PMID: 42966645)
HAA prevalence in Florida ICU | Retrospective medical record review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | HAA from phlebotomy is well-established; single-center descriptive data adds limited new knowledge |
| Clinical Relevance | 5 | Blood conservation is actionable; knowing local prevalence can drive QI initiatives |
| Population Reach | 5 | HAA is ubiquitous in ICUs; but single-center Florida data limits generalizability |
| Implementation Speed | 6 | Blood conservation protocols (smaller draw volumes, bundled testing) are adoptable now |
| Evidence Strength | 3 | Retrospective medical record review; causality not established; single-center |
Main limitation: Single-center; causality between phlebotomy and anemia not measured; no outcome data linking HAA to mortality/morbidity. Equity implications: Marginalized patients with less healthcare advocacy may undergo more unnecessary testing; equity implications of blood loss in vulnerable populations. Evidence Maturity: Exploratory ✓
Article 9 — Choi & Lee — KMT2A-r AML transcriptomics (PMID: 42966630)
Kinase inhibitor sensitivity in KMT2A-rearranged AML | Retrospective transcriptomic analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | KMT2A-rearranged AML is mechanistically distinct; linking transcriptomic state to kinase inhibitor sensitivity beyond FLT3 is a meaningful contribution |
| Clinical Relevance | 5 | Potential to refine drug selection in a high-risk AML subset; preclinical stage |
| Population Reach | 4 | KMT2A-r AML ~5–10% of adult AML; meaningful unmet need despite small absolute numbers |
| Implementation Speed | 3 | Transcriptomic profiling for drug sensitivity is not standard of care; long path to clinical application |
| Evidence Strength | 4 | Retrospective transcriptomic analysis; medium classification confidence; no prospective validation |
Key quantitative result: Not reported in abstract. Main limitation: Retrospective, computational — not validated prospectively; medium-confidence classification; abstract-only. Equity implications: AML disproportionately affects older adults; precision medicine tools may initially concentrate in academic centers. Evidence Maturity: Revised → Exploratory (appropriate)
Article 10 — Goldman — DSRCT therapeutic target atlas (PMID: 42966626) 🟡
Therapeutic targets in desmoplastic small round cell tumor | Multi-cohort transcriptomic study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | DSRCT is an ultra-rare cancer with virtually no effective therapies; a systematic route-aware target atlas is a meaningful foundational resource |
| Clinical Relevance | 5 | Identifies candidates; RNA expression alone does not confirm druggability — but for a disease with no good options, even this is significant |
| Population Reach | 3 | Ultra-rare (~200–300 US cases/year); high relative unmet need justifies attention despite small absolute numbers |
| Implementation Speed | 3 | Requires extensive preclinical and clinical follow-up; no near-term translation expected |
| Evidence Strength | 5 | Two-cohort design provides some reproducibility; 61 patients is reasonable for this ultra-rare disease; RNA-only limits conclusions |
Key quantitative result: Candidate targets detected in all 61 patients across two cohorts; specific targets not named in abstract. Main limitation: RNA-level only; therapeutic accessibility, efficacy, and safety explicitly unconfirmed; small N inherent to disease rarity. Equity implications: DSRCT predominantly affects young males; often diagnosed late; rare disease equity concerns around diagnosis delays and access to clinical trials. Evidence Maturity: Exploratory ✓ (relative to rare disease population, this is meaningful early work)
Article 11 — Vrancianu et al. — Raman spectroscopy for glioma (PMID: 42966518)
Raman spectroscopy in glioma diagnostics | Systematic review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Raman spectroscopy for intraoperative/diagnostic glioma classification is an emerging modality; systematic review adds clarity |
| Clinical Relevance | 5 | Glioma diagnosis and grading are critical; technology shows promise but is far from standard use |
| Population Reach | 4 | Glioma ~25,000 new US cases/year; relevant but not common |
| Implementation Speed | 3 | Substantial methodological standardization required before clinical deployment |
| Evidence Strength | 5 | Systematic review; limited by heterogeneous included studies; no pooled quantitative estimate possible |
Main limitation: Heterogeneous protocols; no external validation; predominantly retrospective single-center primary studies. Equity implications: Specialized optical equipment; likely to concentrate in well-resourced neurosurgical centers initially. Evidence Maturity: Exploratory ✓
Article 12 — Yang et al. — GLP-1 RAs in MASLD cardiovascular outcomes (PMID: 42966342)
GLP-1 agonists and CV outcomes in MASLD | Propensity-matched cohort + mouse study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GLP-1 benefit in MASLD with cardiac endpoints is an active area; propensity-matched + mechanistic animal data adds value |
| Clinical Relevance | 6 | MASLD + CV risk is a major clinical challenge; GLP-1 agonists are widely used — this adds a specific MASLD signal |
| Population Reach | 8 | MASLD affects ~25–30% of adults globally; CV risk in this population is enormous |
| Implementation Speed | 5 | GLP-1 agonists are already prescribed; specific MASLD indication would require label expansion and guideline updates |
| Evidence Strength | 5 | Propensity matching reduces but doesn't eliminate confounding; mixed-species adds mechanistic insight but not clinical certainty; abstract-only |
Key quantitative result: Not quantitatively specified in abstract; described as improvement in cardiac functional indices and molecular remodeling. Main limitation: Observational design; mouse mechanistic data not directly translatable; abstract-only access. Equity implications: GLP-1 agonists are expensive; MASLD disproportionately affects lower-income populations with less drug access. Evidence Maturity: Revised → Exploratory (propensity-matched observational + preclinical does not meet "Validated")
Article 13 — Khan et al. — HTN+hyperlipidemia mortality trends (PMID: 42966230)
US hypertension-hyperlipidemia mortality projections | Ecological study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Trend data from CDC WONDER is a known methodology; projections to 2035 add modest value |
| Clinical Relevance | 5 | Policy-relevant but does not change individual patient management directly |
| Population Reach | 9 | Hypertension affects ~50% of US adults; hyperlipidemia similarly prevalent — massive population |
| Implementation Speed | 4 | Policy changes are slow; surveillance data informs but does not immediately change practice |
| Evidence Strength | 4 | Ecological design; no individual-level data; cannot control for confounders at population level |
Key quantitative result: Mortality "rose substantially" with "marked disparities" — specific rates not extractable from abstract. Main limitation: Ecological fallacy risk; no causal inference; projections depend on trend assumptions that may not hold. Equity implications: Explicitly identifies racial/ethnic mortality disparities — directly equity-relevant; findings call for targeted prevention in underserved communities. Evidence Maturity: Exploratory ✓
Article 14 — Wannaphut et al. — TP53-mutated AML immunotherapy review (PMID: 42966670)
Immunotherapy in TP53-mutated AML | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TP53-mutated AML immunotherapy is an active area; this review synthesizes the landscape but does not add primary data |
| Clinical Relevance | 6 | TP53-mutated AML is a high-risk subtype with poor outcomes; synthesizing the immunotherapy landscape has real clinical value |
| Population Reach | 5 | TP53 mutations in AML ~8–12% of cases; high unmet need |
| Implementation Speed | 3 | Strategies discussed are largely investigational |
| Evidence Strength | 3 | Narrative review — no systematic methodology; synthesis quality depends on author selection |
Main limitation: Narrative review subject to selection bias; no quantitative synthesis; no primary data. Equity implications: AML disproportionately affects older adults; access to novel immunotherapy trials is limited outside academic centers. Evidence Maturity: Exploratory ✓
Article 15 — Silva et al. — Salivary FTIR spectroscopy review (PMID: 42966635)
Salivary ATR-FTIR for systemic diseases | Scoping review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Non-invasive salivary diagnostics is appealing; FTIR for systemic disease detection is emerging |
| Clinical Relevance | 4 | Promising concept but no validated clinical application yet |
| Population Reach | 7 | Systemic diseases are ubiquitous; non-invasive salivary testing could have broad reach if validated |
| Implementation Speed | 2 | Substantial standardization, validation, and regulatory work needed |
| Evidence Strength | 3 | Scoping review; no external validation in primary studies; high heterogeneity |
Main limitation: No standardized protocols; absence of true external validation; clinical translation timeline is long. Equity implications: Non-invasive saliva-based testing could democratize diagnostics if validated; currently academic/research only. Evidence Maturity: Exploratory ✓
Article 16 — Dong et al. — Multi-omics PTM profiling in CRC (PMID: 42966632)
Post-translational modifications in CRC RNA-binding proteins | Multi-omics study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PTM profiling of RNA-binding proteins in CRC is a less-explored angle; FLNA as a multi-PTM candidate is novel |
| Clinical Relevance | 4 | Exploratory molecular target; very early stage |
| Population Reach | 6 | CRC is the third most common cancer globally |
| Implementation Speed | 2 | Early discovery phase; many steps before clinical relevance |
| Evidence Strength | 4 | Multi-omics is methodologically sound; medium confidence; abstract-only; no functional validation described |
Main limitation: Purely computational/correlative; FLNA's functional role in CRC not established; medium classification confidence. Evidence Maturity: Exploratory ✓
Article 17 — Niss et al. — CRF2 agonism in preclinical obesity (PMID: 42966498) ⚪
UCN2 analogues for obesity | Preclinical animal study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | CRF2 agonism as a muscle-preserving obesity treatment is mechanistically novel and differentiated from GLP-1 class |
| Clinical Relevance | 3 | Animal study only; cannot exceed 5 per rules; muscle-preserving obesity treatment is a real unmet need |
| Population Reach | 8 | Obesity affects 40%+ of US adults; muscle-wasting on GLP-1 therapy is an emerging concern |
| Implementation Speed | 2 | Preclinical; regulatory pathway, human trials, and safety data needed |
| Evidence Strength | 4 | Well-designed preclinical study; animal-to-human translation uncertain |
Main limitation: Animal model only; long translation path; GLP-1 combination not tested in humans; abstract-only. Equity implications: Novel obesity pharmacotherapy could benefit underserved populations if cost-accessible. Evidence Maturity: Exploratory ✓
Article 18 — Su et al. — M1 macrophage nanoplatform for solid tumors (PMID: 42966454) ⚪
Nanoimmunotherapy via ASNS-mTOR disruption | Preclinical
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Macrophage membrane camouflage + metabolic-immune dual targeting is a creative and novel approach |
| Clinical Relevance | 3 | Preclinical; cannot exceed 5 per rules |
| Population Reach | 6 | Solid tumors broadly; no specific cancer type specified |
| Implementation Speed | 2 | Early preclinical; manufacturing complexity is high |
| Evidence Strength | 4 | Preclinical in vitro + xenograft; no syngeneic immunocompetent model described |
Main limitation: Preclinical only; xenograft models don't fully capture immune context; manufacturability not addressed. Evidence Maturity: Exploratory ✓
Article 19 — Chandel et al. — SGLT2i genitourinary infections review (PMID: 42966404)
SGLT2 inhibitor infection risk | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Well-established side effect profile; review adds little new insight |
| Clinical Relevance | 6 | Clinically useful to confirm manageable infection risk and drug interaction patterns for prescribers |
| Population Reach | 8 | SGLT2 inhibitors prescribed to millions globally for diabetes and heart failure |
| Implementation Speed | 7 | Guides current prescribing; no adoption barrier |
| Evidence Strength | 3 | Narrative review; subject to selection bias; no meta-analysis |
Main limitation: Narrative review; no systematic methodology; established knowledge base limits novelty. Evidence Maturity: Exploratory ✓
Article 20 — Mehrabi et al. — MYBL2 biomarker in LSCC (PMID: 42966320)
ML-identified MYBL2 as LSCC biomarker | Computational study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Integration of single-cell + bulk RNA-seq + ML for LSCC biomarker discovery is methodologically current |
| Clinical Relevance | 4 | Computational discovery; no clinical validation |
| Population Reach | 4 | LSCC ~13,000 US cases/year; relatively narrow |
| Implementation Speed | 2 | Computational discovery stage; biomarker validation path is long |
| Evidence Strength | 4 | Computational methodology sound; medium confidence; no prospective validation; abstract-only |
Evidence Maturity: Exploratory ✓
Article 21 — Park et al. — Mitochondrial transfer in NK cells (PMID: 42966058) ⚪
Mitochondria-boosted NK cells vs. tumors | Preclinical
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Mitochondrial transfer to enhance NK cell immunotherapy is mechanistically innovative and biologically elegant |
| Clinical Relevance | 3 | Preclinical; cannot exceed 5 per rules; but NK cell therapy is an active clinical development area |
| Population Reach | 6 | NK cell therapies being developed broadly across cancers |
| Implementation Speed | 2 | Complex manufacturing challenge; no human data |
| Evidence Strength | 4 | In vitro + xenograft; promising but standard early-stage design |
Main limitation: Xenograft models lack intact immune system; manufacturing scalability of mitochondria transfer not addressed; abstract-only. Evidence Maturity: Exploratory ✓
Article 22 — Schumann et al. — AI in axial spondyloarthritis imaging (PMID: 42966032)
AI for SpA imaging | Narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI in musculoskeletal imaging is a broad field; SpA-specific review is useful but not groundbreaking |
| Clinical Relevance | 6 | SpA diagnosis is often delayed by years; AI matching expert readers with external validation is clinically meaningful |
| Population Reach | 6 | Axial SpA affects ~0.5–1% of adults globally — a substantial population with significant diagnostic delay |
| Implementation Speed | 5 | Some models appear ready for prospective evaluation; regulatory pathway needed |
| Evidence Strength | 4 | Narrative review; external validation mentioned for some models but review-level synthesis limits confidence |
Evidence Maturity: Exploratory ✓
Article 23 — Wang et al. — Single-cell AST imaging (PMID: 42965887)
Rapid phenotypic antimicrobial susceptibility testing | In vitro method study
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Single-cell morphodynamic imaging for rapid AST capturing heterogeneity is genuinely novel and technically impressive |
| Clinical Relevance | 3 | In vitro only; but rapid AST is a major antimicrobial stewardship need |
| Population Reach | 7 | Antimicrobial resistance is a global health threat affecting all populations |
| Implementation Speed | 3 | Requires specialized imaging hardware and clinical validation; medium-term path |
| Evidence Strength | 5 | In vitro validation study; rigorous for its stage; no clinical sample validation described |
Main limitation: In vitro only; no clinical sample validation; hardware requirements unclear for widespread deployment. Evidence Maturity: Exploratory ✓
Article 24 — Zheng et al. — MAP7D2 knockdown in LUAD (PMID: 42965843) ⚪
MAP7D2 silencing enhances T-cell response in lung cancer | Preclinical
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | MAP7D2 as an immune modulator in LUAD is relatively unexplored; syngeneic model with CD8+ mechanistic link is methodologically appropriate |
| Clinical Relevance | 3 | Animal study; cannot exceed 5 |
| Population Reach | 7 | Lung adenocarcinoma is a major global cancer burden |
| Implementation Speed | 2 | Early preclinical discovery; translation path is long |
| Evidence Strength | 4 | Syngeneic immunocompetent model is a strength; no human validation |
Evidence Maturity: Exploratory ✓
Article 25 — Thakur et al. — mRNA-CRISPR delivery for choroidal melanoma (PMID: 42965688) 🟡
Gene editing nanodelivery in choroidal melanoma | Preclinical narrative review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual-vector mRNA-CRISPR for ocular melanoma is novel in concept; review of preclinical field adds synthesis value |
| Clinical Relevance | 3 | Narrative review of preclinical data; rare disease with high unmet need |
| Population Reach | 3 | Choroidal melanoma ~2,500 US cases/year; very rare but high unmet need justifies attention |
| Implementation Speed | 2 | Preclinical stage; complex regulatory, manufacturing, and ocular delivery challenges |
| Evidence Strength | 3 | Narrative review of preclinical studies; no new primary data |
Evidence Maturity: Exploratory ✓
Article 26 — Ernste et al. — Arrayed CRISPR T-cell screening in CLL (PMID: 42965525)
CRISPR screening platform for T-cell engager combinations | Methods/Lab
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Autologous patient-matched T-cell CRISPR screening for combination target prioritization is a genuinely enabling platform technology |
| Clinical Relevance | 3 | In vitro platform; no clinical data; long path to patient benefit |
| Population Reach | 5 | CLL is common; broad applicability of platform beyond CLL is possible |
| Implementation Speed | 2 | Platform technology; requires specialized expertise and patient sample acquisition |
| Evidence Strength | 4 | In vitro lab study; platform validation appropriate for stage; no clinical correlation |
Evidence Maturity: Exploratory ✓
Article 27 — Mino-León et al. — Polypharmacy and GFR in older adults (PMID: 42965503)
Polypharmacy and reduced GFR in older hypertensive men | Cross-sectional
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Polypharmacy-kidney risk link is established; gender-stratified hypertension interaction adds some nuance |
| Clinical Relevance | 6 | Directly actionable: medication review in hypertensive older men could reduce renal decline |
| Population Reach | 7 | Polypharmacy in older adults is extraordinarily common; hypertension prevalence is high |
| Implementation Speed | 7 | Medication review/deprescribing is immediately actionable by geriatricians and primary care |
| Evidence Strength | 4 | Cross-sectional; cannot establish causality; abstract-only; Mexico-based cohort limits generalizability |
Key quantitative result: Progressive dose-dependent GFR reduction with number of drugs; specific ORs not reported in abstract. Equity implications: Older men in Latin American settings are explicitly studied — underrepresented in many polypharmacy studies; relevant for equity in aging care. Evidence Maturity: Exploratory ✓
Article 28 — Dong et al. — Multi-omics PTM profiling in CRC (PMID: 42966632)
(Already scored as Article 16 above)